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Introduction: The nCD64 receptor, the soluble triggering receptor expressed in myeloid cells 
(s-TREM-1), and the high mobility group-box 1 protein (HMGB-1) have been proposed as significant 
mediators in sepsis. 
Objective: To evaluate the prognostic value of these markers in patients with suspected infection 
recently admitted in an emergency department (ED).
Materials and methods: All patients who presented to the ED with suspected infection were eligible 
for enrollment in this study. Baseline clinical data, Sequential Organ Failure Assessment score (SOFA) 
score, APACHE II score, HMGB-1 levels, s-TREM-1 levels, and nCD64 levels were analyzed. The 
HMGB-1 and sTREM-1 serum concentrations were determined using commercially available ELISA 
kits, and CD64 on the surface of neutrophils was measured by flow cytometry.
Results:. A total of 579 patients with suspected infection as their admission diagnosis were enrolled 
in this study. The median patient age was 50 years (IQR = 35-68).  Morbidity during the 28-day follow-
up period was 11.1% (n=64). The most frequent diagnosis at the time of admission was community-
acquired pneumonia (CAP) in 23% (n=133) patients, followed by soft tissue infection in 16.6% (n=96), 
and urinary tract infection in 15% (n=87). After multivariable analysis, no significant association was 
identified between any biomarker and 28-day mortality.
Conclusion: In the context of a tertiary care hospital emergency department in a Latin-American city, 
the nCD64 receptor, s-TREM-1, and HMGB-1 biomarkers do not demonstrate prognostic utility in the 
management of patients with infection. The search continues for more reliable prognostic markers in 
the early stages of infection.
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Caracterización de la expresión de nCD64 en neutrófilos y de los niveles de s-TREM-1 y HMGB-1 
en pacientes con sospecha de infección admitidos en el departamento de emergencias
Introducción. El receptor CD64, receptor soluble ‘desencadenador’ expresado en células mieloides 
(sTREM-1) y la proteína del grupo Box-1 de alta movilidad (HMGB-1), se han propuesto como 
mediadores en la sepsis. 
Objetivo. Evaluar el valor pronóstico de estos marcadores en pacientes con sospecha de infección, 
recientemente admitidos en un departamento de emergencias.
Materiales y métodos. Se incluyeron en el estudio pacientes que consultaron al hospital con sospecha 
de infección. Se analizó la base de datos clínica, el puntaje SOFA, el puntaje APACHE II, los niveles 
de HMGB-1, los niveles de sTREM-1 y los niveles de nCD64. Se determinaron las concentraciones 
644
Biomédica 2013;33:643-52Velásquez S, Matute JD, Gámez LY, et al.
en suero de HMGB-1 y sTREM-1, usando kits de ELISA disponibles comercialmente, y la de CD64 se 
midió por citometría de flujo.
Resultados. Se analizaron 579 pacientes con sospecha de infección al ingreso. La edad media fue 
de 50 años (rango intercuartílico=35-68), y 11,1 % (n=64) murieron durante el seguimiento de 28 días. 
El diagnóstico más frecuente en el momento del ingreso fue neumonía adquirida en la comunidad, en 
23 % (n=133) de los pacientes, seguida de infección de tejidos blandos, en 16,6 % (n=96), e infección 
urinaria, en 15 % (n=87). Después de un análisis multivariado, no hubo asociación significativa entre 
ningún biomarcador y la mortalidad a los 28 días.
Conclusión. Los resultados sugieren que en el contexto de un departamento de emergencias de 
tercer nivel de una ciudad latinoamericana típica, los tres marcadores evaluados no ofrecieron ninguna 
ventaja en el pronóstico de infección. La búsqueda de marcadores pronósticos más confiables en 
estadios tempranos de la infección aún continúa abierta.
Palabras clave: pronóstico, infección, neutrófilos, pacientes, urgencias médicas
doi: http://dx.doi.org/10.7705/biomedica.v33i4.805
Infectious disease and sepsis are serious 
conditions with significant morbidity and mortality. 
The prevalence of sepsis among inpatients 
varies between 2% and 11% (1,2), but little is 
known about how to identify patients who have 
increased risk for mortality from infection. A need 
exists to identify biomarkers to accurately identify 
subpopulations of individuals with infection who 
are at risk for increased mortality, for the purposes 
of prognostication and development of targeted 
therapies towards specific biomarkers or related 
biologic processes. Moreover, previous reports 
have shown that early therapy improves survival 
and clinical outcomes (3,4).
Several markers have been suggested to facilitate 
and inform prognosis in patients with infection. 
The cluster of differentiation-64 (CD64), soluble 
triggering receptor expressed on myeloid cell-1 
(s-TREM-1), and high-mobility group box-1 
(HMGB-1) are considered to be promising new 
biomarkers in the context of infection, and they 
have been studied primarily in the intensive 
care unit setting (5). CD64 is a high affinity 
immunoglobulin Fc receptor I (FcRI) (6), which is 
expressed in monocytes and macrophages and is 
virtually undetectable on mature neutrophils from 
healthy individuals (1). CD64 levels increase within 
hours, both in vitro and in vivo, in the presence of 
inflammatory mediators such as interferon-gamma, 
granulocyte colony stimulating factor (G-CSF), 
immunoglobulin G (IgG), and complement 
opsonized particles (1,2,5). CD64 levels also have 
been shown to increase rapidly in infected patients 
(7). TREM-1 is a cell surface molecule present on 
neutrophils and mature monocytes and is actively 
expressed in response to infection by bacteria or 
fungi (8). TREM-1 can be released as a soluble 
molecule (s-TREM-1) in response to microbial 
products before the occurrence of the classic clinical 
findings of sepsis (8). Some reports have shown 
high levels of sTREM-1 in biologic fluids of patients 
with infections (8,9). Furthermore, Gibot et al found 
that sTREM-1 levels were constitutively elevated in 
all non-surviving patients, whereas sTREM-1 levels 
rapidly decreased in survivors during the first week 
after study admission (8). HMGB-1 is a cytokine-
like mediator of inflammation, and it is released 
later in the inflammatory process as compared 
to the classical ‘alarm-phase’ cytokines, such as 
TNF and interleukin (IL)-1β. Clinical reports reveal 
that HMGB-1 levels were increased significantly in 
critically ill patients with sepsis (10), severe sepsis, 
and septic shock, with levels remaining high in non-
survivors (5).
This clinical study aimed evaluate the prognostic 
value of nCD64, s-TREM-1, and HMGB-1 in patients 
with suspected infection admitted in an Emergency 
Department (ED), using 28-day mortality as a 
metric for prognosis. We selected 28-day mortality 
as our primary outcome because this period of time 
frequently covers the most significant changes in 
clinical response in sepsis and also is an accepted 
clinical end-point in the critical care population. 
Previous research with the same study population 
evaluating the same biomarkers as diagnostic tests 
has been previously published (11).
Materials and methods
We prospectively recruited patients with suspected 
infection who presented to the ED of a tertiary care 
level hospital in Medellin, Colombia. 
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Study design
This was a prospective cohort study. The patients 
in this study were part of the population of a larger 
study “Toward an operative diagnosis in sepsis: 
a latent class approach” (12). The local scientific 
ethical committee approved sample collection on 
the basis of verbal informed consent.
Study setting and population
The study setting was an ED at the Hospital 
Universitario San Vicente de Paúl (Medellin, 
Colombia). This is a 550-bed fourth level University 
Hospital with an admission rate of approximately 
1,800 patients per month through the ED, and it is 
a reference institution for a region of approximately 
4 million habitants. Patient enrollment began on 
July 2007 and concluded on September 2008. All 
patients were greater than or equal to 18 years of 
age, and were evaluated in the ED within 24 hours 
before recruitment to the study. The only inclusion 
criterion for entry to this study was suspected 
infection by the treating doctor. Exclusion criteria 
included the following: 1) screening for the study 
more than 24 hours after admission to the hospital; 
2) refusal of the patients, their families, or the 
attending physician to be part of the study; 3) 
antimicrobial treatment received in other medical 
institution immediately before the beginning of 
the study; 4) medical decision to treat the patient 
ambulatory or in a different institution within 24 
hours after admission; 5) homelessness or inability 
of the patient to follow-up at 28 days; and 6) 
previous participation in the same study. 
Data collection and processing
Three physicians and two trained nurses recruited 
patients by checking admission lists and clinical 
records on a daily basis from Monday to Saturday. 
The general protocol for each patient after 
recruitment was as follows: 1) collection of baseline 
clinical data; 2) calculation of entrance Sepsis 
Organ Failure Assessment (SOFA) score (13) and 
Acute Physiology and Chronic Health Evaluation 
(APACHE II) score (14); and 3) blood sampling 
(two EDTA and two anticoagulant free tubes with 
separation gel). All of these steps occurred within 
24 hours of the first ED evaluation. A standard case 
report form was used to record daily progression of 
patients by reviewing medical and nursing records 
until the time of discharge or death. In patients who 
left the hospital alive, the vital status was verified at 
day 28 through a telephone call. 
Methods of measurement
Laboratory techniques
The serum samples (anticoagulant free tube with 
separation gel) were separated by centrifugation 
at 2,000 rpm over 20 minutes within 2 hours 
after bleeding to avoid false elevation of levels of 
HMGB-1 secondary to passive release from the 
intracellular compartment (15). Samples then were 
stored at -70oC for later analysis of s-TREM-1 and 
HMGB-1. Blood specimens remain acceptable for 
up to 8 hours when held at room temperature (18-
22°C) or for 48 hours when refrigerated (2-8°C) 
(16). The measurement of nCD64 from EDTA 
tubes was made less than 15 hours after blood 
extraction. All the procedures were performed by 
laboratory technicians who were blinded to clinical 
data. The handling of samples and the techniques 
for biomarkers measurement described below were 
similar to those used in previous reports (5,6).
Serum HMGB-1 levels were determined using 
commercially available ELISA following manufacturer 
instructions (Human HMGB-1 Kit cat No. 326052202, 
Shino –Test Corporation 2-29-14, Oonodai, 
Sagamihara-shi, Kanagawa 229-0011, Japan). The 
lower limit of detection of the test is 1 ng/ml. The cross 
reaction to HMGB-2 is less than 2% and the coefficient 
of variation was 10%. s-TREM-1 serum concentration 
was determined by ELISA (Kit Quantikine, Human 
TREM-1 Immunoassay, cat no. DTRM10, R&D 
Systems, Inc. Minneapolis, MN, USA). The lower limit 
detection of the test is 3.88 pg/ml. ELISA results were 
quantified using a microplate reader set POWER 
WAVE X (Biotek Instruments Inc). The inter- and 
intra-assay coefficient of variation for the s-TREM 
and HMGB-1 tests were <10%. nCD64 levels were 
measured with the Leuko 64 kit (Reference: LK64-
250 – Trillium Diagnosis, LLC, Brewer, Maine, USA 
04412) using a COULTER EPIC XL flow cytometer 
using Leuko64TM software (included in the kit). The 
results were expressed in Molecules of Equivalent 
Soluble Fluorochrome (MESF) units (17), and then 
compared with the expression of positive control 
(monocytes) and negative control (lymphocytes). 
Data analysis
According to the available literature and the 
established biological basis of infection, we 
considered as potential confounders age, sex, 
lactate, APACHE II and SOFA scores, and comorbidity 
including diabetes mellitus, chronic renal disease, 
chronic obstructive pulmonary disease, use of 
steroids or chemotherapy in the previous three 
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months, history of cancer in the previous year, HIV/
AIDS, solid organ transplantation, cirrhosis, and 
trauma (1,2,12). Comorbidity data were obtained 
from medical records of each patient, and a 
dichotomous variable was defined as the presence 
of at least one of the comorbidities mentioned above. 
For continuous variables, expressed as medians 
with interquartile ranges (IQR) or as means with 
standard deviations, we used the Mann-Whitney U 
or Student’s t-test (depending on data distribution) 
to investigate the differences between survivors 
and non-survivors. We performed a logistic 
regression analysis including variables of interest 
in accordance to those previously defined. The 
potential linear relation between the continuous 
independent variables and the logarithm of odds 
of the outcome (“logit”) was explored by graphical 
representations of locally weighted (“lowess”) 
nonparametric regression models (18). Biomarkers 
were also explored through their transformation 
into dummy variables based on their classification 
in tertiles, and using the first tertile as reference. 
Multicollinearity was assessed by measuring the 
variance inflation factor (VIF) and verifying that 
its value for each variable was less than 10 (19). 
We evaluated the possible interaction between 
the biomarkers and sex, as well as the interaction 
between the biomarkers and the severity of sepsis 
as measured by SOFA, using a logistic model by 
means of the likelihood ratio test (LR test), comparing 
the full and the nested model, and considering as 
significant p values of less than 0.1 (20). Given the 
obtained sample size, we tried to follow the rule of 
at least 10 outcomes per independent variable in 
the logistic regression analysis whenever possible 
(21,22). Results are presented as Odds Ratio (OR) 
with their 95% confidence intervals. All tests were 
performed using STATA SE statistical software 
(Version 10, College Station, TX, USA).
Results
During the study period, 1340 eligible patients 
were admitted to the emergency service and 761 
were excluded based on previously described 
exclusionary criteria (figure 1). We analyzed 579 
patients with suspected infection as their admission 
diagnoses, 64 (11.1%) of whom died during the 
28-day follow up period. The median age was 50 
years (IQR = 35-68), and there were approximately 
equal numbers of males and females (298 females, 
51.5%). The median time of symptoms before 
consultation was 72 hours (IQR = 36-192), and the 
median hospital length of stay was 9 days (IQR = 
5-17). Two hundred and forty-six (37.6%) patients 
had no associated comorbidity. In those patients 
with comorbidity, the most frequent conditions 
Figure 1. Flow chart of recruitment and patient status.
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were diabetes mellitus in 125 (19.2%), chronic 
kidney disease in 72 (11.2%), chronic obstructive 
pulmonary disease in 70 (10.7%), exposure to 
steroids or chemotherapy during the previous 3 
months in 57 (8.7%), and history of cancer during 
the previous year in 56 (8.5%) patients. The median 
APACHE II score on admission was 10 (IQR=6-
15) and the median SOFA score was 2 (IQR=1-4). 
The main clinical and laboratory characteristics 
according to vital status are presented in table 1. 
The most frequent diagnosis at the time of admission 
was community-acquired pneumonia (CAP) in 133 
patients (23%), followed by soft tissue infection 
in 96 patients (16.6%), urinary tract infection in 
87 patients (15%), intra-abdominal infection in 65 
patients (11.2%), and clinical sepsis according to 
CDC definitions (21) in 56 patients (9.7%). Other 
identified infections included gastroenteritis, 
reproductive tract infection, deep surgical site 
infection, skin infection, catheter-associated 
urinary tract infection, endometritis, other lower 
respiratory tract infections, tracheobronchitis, 
other gastrointestinal infections, upper respiratory 
tract infection, otitis and mastoiditis, endocarditis, 
meningitis or ventriculitis, arthritis, osteomyelitis, 
bloodstream infection, and organ/space surgical 
site infection. A microbiological diagnosis was 
confirmed in 287 (43.9%) patients, 112 (39%) of 
them with positive blood cultures.
Prognostic value of biomarkers and severity 
scores
Figure 2 shows a representative flow cytometry 
analysis of nCD64 in the study population, and 
the values of each biomarker stratified by clinical 
diagnosis are shown in table 2. There were not 
significant differences between biomarker values 
in the study population according to previous use 
of steroids/chemotherapy or history of cancer (data 
not shown). The factors potentially associated 
with 28-day mortality, according to the logistic 
regression analysis, are presented in table 3. 
Although the univariable analysis showed a 
significant association between 28-day mortality 
and the highest tertiles of nCD64 and s-TREM-1 
levels (OR = 2.06, 95% CI: 1.06; 4.00 and OR = 4.5, 
95% CI: 2.12; 9.55, respectively), this relationship 
disappeared after multivariable analysis. These 
findings were confirmed in a model considering 
biomarkers as continuous variables, as well as 
in logistic models with backward and forward 
stepwise estimation procedures. There was no 
evidence of multicollinearity (VIF < 2) or interaction 
between biomarkers and sex (p > 0.2 for all the 
Table 1. Baseline clinical data according to the 28-day survival status*
Characteristics Survivors (n=512) Non-survivors (n=64)
Age in years 49 (33-66) 64 (41-77)
SOFAa score 2 (1-4) 4 (3-6)
APACHEb II score  9 (5-14) 12 (10-18)
CD64 (MESFc) 1.8 (1.2-3.1) 2.4 (1.4-3.6)
S-TREM (pg/ml) 140 (19.6-352.9) 373 (169-700)
HMGB1 (ng/ml) 8.1 (2.3-16.3) 9.3 (4.1-19.0)
Maximum temperature (°C) 37 (36-37) 37 (36-37)
Maximum heart rate (beats/min) 93 (82-108) 107 (91-119)
Maximum respiratory rate (breaths/min) 20 (18-27) 28 (20-32)
Minimum systolic blood pressure (mm Hg) 106 (95-121) 100 (87-121) 
Minimun diastolic blood pressure (mm Hg) 62 (54-70) 60 (50-67) 
Mimimun mean blood pressure (mm Hg) 77 (68-87) 72 (61-90)
Leucocytes (cells/mm3) 11,600 (8,500-16,600) 11,450 (8,100-14,000)
Neutrophils (%) 80 (70-88) 81 (73-90)
Platelets (cells/mm3) 291,000 (218,000-391,000) 223,000 (111,000-361,000)
Bilirrubine (mg/dl) 0.7 (0.5-1) 0.9 (0.6-2.2)
Creatinine (mg/dl) 1 (0.8-1.5) 1.3 (0.8-2.2)
PaO2/FiO2  317 (238-379) 235 (140-301)
Comorbidityd (%) 264 (51.6) 41 (64.1)
Positive blood cultures (%)e 61 (21) 11 (24)
* Survival status at 28-day was unknown for three participants. 
Data are presented as median (IQR) or absolute numbers and percentages. a SOFA: Sepsis-related Organ Failure Assessment 
score. b Acute Physiological and Chronic Health Evaluation. c MESF: Molecular equivalent soluble fluorochrome (17). d At least one 
comorbility: diabetes mellitus, chronic kidney disease, chronic obstructive pulmonary disease, use of steroids or chemotherapy in the 
previous 3 months or history of cancer during the previous year. e Percentage of positive blood cultures among total blood cultures 
requested.
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comparisons) or between biomarkers and SOFA (p 
> 0.3 for all the comparisons).
Discussion
Cytokines are key mediators during early phases 
of infection and sepsis, and increased serum levels 
of cytokines are associated with the intensity of the 
inflammatory response. The value of prognostic 
markers in sepsis lies in their ability to identify 
subpopulations of patients with increased mortality 
risk who might benefit from specific therapies 
Figure 2. Flow cytometry analysis of nCD64 in the study population
Table 2. Main admission diagnosis and its respective biomarkers value
Main diagnosis at admission nCD64 HMGB-1 s-TREM-1
 MESF pg/ml ng/ml
Community-acquired pneumonia  2.1 (1.4-3.2) 8.2 (1.2-19) 185.4 (57.2-454.2)
Urinary tract infection 2.8 (1.6-4.2) 8.4 (4.1-16) 220.5 (77.1-409.2)
Soft tissue infection  1.7 (1.0-2.7) 9.6 (4.7-19) 212.3 (83.4-476.7)
Clinical sepsis  3.2 (2.3-4.5) 7.8 (3.3-16.3) 411.7 (153.6-694.7)
Intra-abdominal Infection  2.6 (1.8-3.5) 11.1 (5.3-23) 192 (81-465)
Superficial surgical site infection 1.7 (1.4-2.3) 9.6 (6.4-15.4) 174 (101.2-218)
Gastroenteritis 2.7 (1.7-4.1) 8.7 (2.3-12) 111.2 (0-282.7)
Reproductive tract infection  3.6 (3-5) 19.7 (9.8-25.8) 264.3 (55.3-354.3)
Deep surgical site infection  1.5 (0.9-2.3) 8.7 (16.2-4.7) 115 (0-190)
Skin infection  1.9 (0.9-2.3) 4.2 (1.9-9.8) 74.7 (15.0-116.4)
Catheter-associated urinary tract infection 3.4 (2.1-4.7) 9.7 (4.4-10) 540.8 (253-758.3)
Data are presented as median and interquartile range
targeted at biochemical pathways identified by the 
respective biomarker. In this study, we evaluated 
the prognostic value of three biomarkers on 
mortality outcomes of patients with suspected 
infection. Following comprehensive analysis, we 
show that measurement of nCD64, s-TREM-1 
and HMGB-1 serum levels does not have clinical 
utility in prognosis of 28-days mortality for infected 
patients in the ED of this hospital. Only the SOFA 
score was a useful prognostic marker for mortality 
in this study population.
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Previous studies have suggested the utility of 
these three biomarkers as diagnostic metrics in 
the workup of patients with presumed infection. 
Use of these biomarkers to predict outcomes, 
however, have yielded inconsistent results in the 
literature. Livaditis, et al. (23), recently showed that 
increased CD64 neutrophil expression correlates 
with stages of severity and is associated with poor 
outcome in patients with sepsis. Similarly, Song, et 
al., demonstrated that increased neutrophil CD64 
expression correlates to 28-day mortality of patients 
with disseminated intravascular coagulation, 
including patients with sepsis (24). In evaluating 
the prognostic value of a wide range of markers 
reflecting different stages of priming, adhesion, and 
activation of monocytes and neutrophils, Muller et 
al showed that overall increase in the expression 
of markers of neutrophil and monocyte activation 
is related to favorable outcome in septic patients, 
with the exception of CD64 expression, which 
was increased in the non-survivors and reduced 
in survivors (25). Conversely, Danikas et al. found 
that an increased expression of CD64 antigen on 
polymorphonuclear cells (PMNs) and monocytes 
was favorable, but not fully correlated to patient 
survival (26). Consistent with that report, our findings 
did not confirm any independent relationship 
between CD64 levels and 28-day survival. 
Table 3. Logistic regression analysis for 28 day mortality
Variable Univariate Multivariate 
 OR  [95% CI]  OR  [95% CI] 
Age (years) 1.02 [1.01, 1.04] 1.02 [1.01, 1.04]  
Sex 0.86 [0.51, 1.44] 0.62  [0.33, 1.15]  
SOFAa score 1.49 [1.32, 1.67] 1.34  [1.12, 1.62]  
APACHEb score 1.11 [1.06, 1.15] 0.98  [0.92, 1.06]  
Lactate 1.43 [1.23, 1.67] 1.19  [0.98, 1.45]  
Comorbilitiesc 1.67 [0.98, 2.87] 1.00  [0.52, 1.94]  
CD64 tertiles (MESF) d   
nCD64 T1 0. < 1.4 REF REF 
nCD64 T2 ≥ 1.4 & < 2.68 1.45 [0.70-2.99] 1.10 [0.48-2.48] 
nCD64 T3 ≥ 2.68 2.06 [1.06-4.00] 1.18  [0.55-2.55] 
sTREM-1 tertiles (pg/ml)   
sTREM-1 T1 < 80.33 REF REF 
sTREM-1 T2 ≥ 80.33 & < 282.48 1.55 [0.65-3.69] 1.11  [0.43-2.87] 
sTREM-1 T3 ≥ 282.48 4.50 [2.12-9.55] 2.05  [0.83-5.07] 
HMBG-1 Tertiles (ng/ml)   
HMGB-1 T1 < 4.29 REF REF 
HMGB-1 T2 ≥ 4.29 & < 12.07 1.35 [0.68-2.69] 0.98  [0.45-2.12] 
HMGB-1 T3 ≥ 12.07 1.49 [0.77-2.86] 0.95  [0.44-2.06]
 a SOFA: sepsis-related organ failure assessment score 
b Acute physiological and chronic health evaluation 
c At least one comorbility: diabetes mellitus, chronic kidney disease, chronic obstructive pulmonary disease, use of steroids or 
chemotherapy in the previous 3 months, and history of cancer during the previous year. 
d MESF: molecular equivalent soluble fluorochrome (17)
The soluble triggering receptor expressed on 
myeloid cells (s-TREM-1) is a recently identified 
molecule involved in the inflammatory response 
(27). Although the membrane-bound TREM is 
substantially up-regulated during infection (28), the 
soluble form appears to be specifically released 
in pneumonia and sepsis, where high levels of 
s-TREM are observed in serum samples from 
septic shock patients but not in controls. s-TREM-1 
has been shown to be a promising diagnostic tool, 
both in ventilator-related pneumonia (29) and in 
the diagnosis and prognosis of sepsis in critical 
care (30). Reduction of serum values of s-TREM-1 
is also useful to assess the antibiotic response in 
patients with community acquired penumonia (31). 
For patients with ventilator-associated pneumonia, 
Routsi C et al. reports that a sustained increased 
in s-TREM-1 levels from the time of diagnosis is 
associated with poor prognosis (30). Similarly, 
Tejera et al showed that initially increased s-TREM-1 
levels were related to short-term mortality in 
patients with community-acquired pneumonia, 
and its prognosis value was independent of 
advanced age, other markers of inflammation, 
severity indexes, and nutritional status (32). There 
remain inconsistencies in the literature, however, 
with Gibot et al reporting an association between 
low initial serum s-TREM-1 levels and mortality in 
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septic patients, and Latour-Pérez et al showing 
no association between s-TREM-1 and mortality 
after adjustment by severity according to SAPS 3 
score (29,33,34). Our results suggest that the role 
of s-TREM-1 as prognostic marker in infection still 
warrants further study. 
HMGB-1 was originally identified as a nuclear DNA-
binding protein critical for proper transcriptional 
regulation (35). More recently, HMGB-1 has been 
found to act as a “late” inflammatory cytokine that 
contributes to the pathological progression of sepsis 
and other inflammatory disorders (36). In patients 
with severe sepsis, the kinetic of circulating HMGB1 
may differ from the classic mouse model findings 
depending on the primary source of infection (37). 
HMGB-1 has been proven to be a successful 
therapeutic target in experimental models of diverse 
infectious and inflammatory diseases (39). Higher 
levels of HMGB-1 have been shown patients with 
fatal outcome (36, 38), as well as in patients with 
infection as compared to healthy controls (38, 40). 
Other studies, however, have shown no statistically 
significant difference in serum levels of HMGB-1 
between infected and the non-infected patients (40, 
41), using the same commercial kit utilized in this 
study. In the absence of general consensus in the 
literature, the role of HMGB-1 remains debatable, as 
this molecule parallels other severity markers and 
may not provide further specific information regarding 
outcome (5). Our study confirms that serum HMGB-1 
measurement does not have a role at this time in the 
prognosis of patients with infection. 
An important limitation in this study involves kinetics 
of the biomarkers. Specifically, the production and 
release of these molecules varies according to 
the clinical course of the patients and the timing 
of measurements. Patients present to medical 
attention at time points during the course of illness, 
and biomarker peaks may be missed based on 
timing of presentation. 
Our results suggest that, although the biomarkers 
nCD64, s-TREM-1, and HMGB-1 are increased 
during early phases of infection and sepsis, their 
prognostic value is limited. At this time, they are 
not ideal candidates as therapeutic targets, as they 
do not identify subpopulations with increased risk. 
In the context of an Emergency Department of a 
tertiary care hospital in a typical Latin-American 
city, these markers do not offer an advantage in 
infection prognosis. The search for more reliable 
prognostic markers in the early stages of infection 
remains open, and the relative strengths and 
weaknesses of biomarkers must be recognized in 
order to use them rationally.
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